trial

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy – CORRECTION

April 10, 2026 16:09 ET  | Source: Mesoblast Limited Working with Parent Project Muscular Dystrophy and the Duchenne Registry on…

2 days ago

ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406

SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy…

4 days ago

Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

Milestones underscore clinical progress and strengthen commercial foundationLOS GATOS, Calif., April 8, 2026 /PRNewswire/ -- Supira Medical, Inc. (Supira), a clinical-stage…

5 days ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026 15:00 ET  | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…

2 weeks ago

Crescel Reports Positive Randomized Controlled Trial Results for Biobotanical Skin Renewal Cream in Rosacea

Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable TolerabilityMIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC,…

4 weeks ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

1 month ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

1 month ago

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

February 28, 2026 09:45 ET  | Source: Cogent Biosciences, Inc. Bezuclastinib mean TSS reduction deepens to –32.0 points at 48…

1 month ago

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative…

2 months ago

Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

February 13, 2026 17:00 ET  | Source: Ocular Therapeutix, Inc. Ocular to host webcast scheduled for Tuesday, February 17, 2026,…

2 months ago